Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology entities : Regeneron pharmaceuticals, inc. save search
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
asco tumors treatment blood for
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.51%
H: 0.78%
C: 0.18%
KNSA | $17.85 0.96% 0.95% 370K
|
Health Technology
|
| O: 1.06%
H: 6.08%
C: 3.39%
first pharmaceuticals financial results
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-22 (Crawled : 22:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.51%
H: 0.78%
C: 0.18%
genetic cell research therapy
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.09%
H: 0.86%
C: -0.3%
KNSA | $17.85 0.96% 0.95% 370K
|
Health Technology
|
| O: 0.46%
H: 0.17%
C: -3.36%
first report pharmaceuticals financial results
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Published: 2024-04-08 (Crawled : 23:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.31%
H: 0.83%
C: 0.27%
OPT | News | $3.46 2.98% 2.89% 8.2K
|
Health Technology
|
| O: -2.73%
H: 3.57%
C: 3.32%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.37%
H: 0.38%
C: 0.06%
ADVM | News | $10.19 -7.36% -7.95% 310K
|
Health Technology
|
| O: -0.4%
H: 1.52%
C: -4.15%
medical
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.11%
H: 0.32%
C: -0.07%
response
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.7%
first conference report financial results
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Regeneron Provides Update on Biologics License Application for Odronextamab
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.37%
H: 1.15%
C: 0.74%
license update application
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Published: 2024-03-13 (Crawled : 02:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: -1.46%
million cancer research
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.23%
H: 0.9%
C: -0.68%
praluent fda children genetic cholesterol approval treat injection
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.0%
H: 0.27%
C: -0.46%
eylea lancet macular injection diabetic
Opthea Reports Half-Year Financial Results and Business Updates
Published: 2024-02-28 (Crawled : 23:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.23%
H: 0.04%
C: -2.41%
OPT | News | $3.46 2.98% 2.89% 8.2K
|
Health Technology
|
| O: -6.93%
H: 8.63%
C: 8.63%
business financial results
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Published: 2024-02-28 (Crawled : 12:30) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.17%
H: 0.33%
C: -0.74%
KNSA | $17.85 0.96% 0.95% 370K
|
Health Technology
|
| O: 4.93%
H: 0.27%
C: -7.12%
pharmaceuticals financial results
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Published: 2024-02-21 (Crawled : 21:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.08%
H: 2.04%
C: 1.19%
KNSA | $17.85 0.96% 0.95% 370K
|
Health Technology
|
| O: 0.2%
H: 0.25%
C: -1.4%
report pharmaceuticals financial results
Society for Science Fuels Innovation with $110K in Educator Grants, Transforming Classrooms for Student STEM Research
Published: 2024-02-21 (Crawled : 14:30) - prnewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.54%
H: 0.63%
C: 0.09%
innovation research
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.